DC
Therapeutic Areas
TaiMed Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Trogarzo® (ibalizumab) | Multidrug‑resistant HIV‑1 infection | Commercial |
| TMB‑365/TMB‑380 | Long‑acting dual‑antibody therapy for HIV‑1 | Phase 2b |
| TMB‑365 | Monotherapy for HIV‑1 | Phase 2 |
| CD4‑targeted ADC | Autoimmune diseases | Preclinical |